Circadian events in human diseases and in cytochrome P450-related drug metabolism and therapy

IUBMB Life

Volumn 65, Issue 6, 2013, Pages 487-496

  Košir, Rok ^a,b   Španinger, Klemen ^a,b   Rozman, Damjana ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b Slovenia and DiaGenomi Ltd   (Slovenia)

Author keywords

Complex diseases; Drug design; Hemeproteins; Transcription factors; Transcriptional regulation

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARCINOGEN; CELL NUCLEUS RECEPTOR; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 2A5; CYTOCHROME P450 2B9; CYTOCHROME P450 3A11; DOCETAXEL; FLUOROURACIL; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLYCERYL TRINITRATE; HEMOPROTEIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; MITOXANTRONE; NAVELBINE; PROTEIN BMAL1; PROTON PUMP INHIBITOR; ROSCOVITINE; THEOPHYLLINE; TRANSCRIPTION FACTOR CLOCK; UNINDEXED DRUG;

ACUTE HEART INFARCTION; ASTHMA; BIOLOGICAL RHYTHM; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENICITY; CARDIOVASCULAR DISEASE; CHRONOPHARMACOLOGY; CHRONOTHERAPY; CIRCADIAN RHYTHM; DETOXIFICATION; DISEASE PREDISPOSITION; DRUG ABSORPTION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INFUSION; DRUG METABOLISM; E BOX ELEMENT; ENERGY METABOLISM; ENZYME ACTIVITY; EVENING DOSAGE; GLUCONEOGENESIS; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHALAMUS; LIPID OXIDATION; LIPOGENESIS; LIVER BLOOD FLOW; MEDICAL PRACTICE; MORNING DOSAGE; MULTIGENE FAMILY; NEOPLASM; NONHUMAN; OVARY CANCER; PERSONALIZED MEDICINE; PROMOTER REGION; PROSTATE CANCER; PROTEIN DEGRADATION; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SHIFT WORKER; SINGLE DRUG DOSE; STOMACH ACID SECRETION; STOMACH ULCER; SUPRACHIASMATIC NUCLEUS; THROMBOCYTE AGGREGATION INHIBITION; TRANSCRIPTION REGULATION; UNSTABLE ANGINA PECTORIS; XENOBIOTIC METABOLISM;

COMPLEX DISEASES; DRUG DESIGN; HEMEPROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL REGULATION;

ANIMALS; ARTHRITIS, RHEUMATOID; ASTHMA; CARDIOVASCULAR DISEASES; CIRCADIAN RHYTHM; CYTOCHROME P-450 ENZYME SYSTEM; DRUG CHRONOTHERAPY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; METABOLIC DETOXICATION, DRUG; NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STOMACH ULCER;

EID: 84881529383     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1160     Document Type: Review

References (54)

1. Green, C. B., Takahashi, J. S., and Bass, J. (2008) The meter of metabolism. Cell 134, 728-742.
2. Sahar, S. and Sassone-Corsi, P. (2009) Metabolism and cancer: the circadian clock connection. Nat. Rev. Cancer 9, 886-896.
3. Schibler, U. and Sassone-Corsi, P. (2002) A web of circadian pacemakers. Cell 111, 919-922.
4. Foster, R. G., Hankins, M. W., and Peirson, S. N. (2007) Light, photoreceptors, and circadian clocks. Methods Mol. Biol. 362, 3-28.
5. Gallego, M. and Virshup, D. M. (2007) Post-Translational modifications regulate the ticking of the circadian clock. Nat. Rev. Mol. Cell Biol. 8, 139-148.
6. Ko, C. H. and Takahashi, J. S. (2006) Molecular components of the mammalian circadian clock. Hum. Mol. Genet. 15, R271-R277.
7. Akashi, M. and Takumi, T. (2005) The orphan nuclear receptor RORalpha regulates circadian transcription of the mammalian core-clock Bmal1. Nat. Struct. Mol. Biol. 12, 441-448.
8. Preitner, N., Damiola, F., Lopez-Molina, L., Zakany, J., Duboule, D., et al. (2002) The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell 110, 251-260.
9. Gehring, W. and Rosbash, M. (2003) The coevolution of blue-light photoreception and circadian rhythms. J. Mol. Evol. 57, S286-S289.
10. Panda, S., Antoch, M. P., Miller, B. H., Su, A. I., Schook, A. B., et al. (2002) Coordinated transcription of key pathways in the mouse by the circadian clock. Cell 109, 307-320.
11. Reddy, A. B., Karp, N. A., Maywood, E. S., Sage, E. A., Deery, M., et al. (2006) Circadian orchestration of the hepatic proteome. Curr. Biol. 16, 1107-1115.
12. Akhtar, R. A., Reddy, A. B., Maywood, E. S., Clayton, J. D., King, V. M., et al. (2002) Circadian cycling of the mouse liver transcriptome, as revealed by cDNA microarray, is driven by the suprachiasmatic nucleus. Curr. Biol. 12, 540-550.
13. Zmrzljak, U. P. and Rozman, D. (2012) Circadian regulation of the hepatic endobiotic and xenobitoic detoxification pathways: the time matters. Chem. Res. Toxicol. 25, 811-824.
14. Gachon, F. and Firsov, D. (2011) The role of circadian timing system on drug metabolism and detoxification. Expert Opin. Drug Metab. Toxicol. 7, 147-158.
15. Yan, J., Wang, H., Liu, Y., and Shao, C. (2008) Analysis of gene regulatory networks in the mammalian circadian rhythm. PLoS Computat. Biol. 4, e1000193.
16. Nelson, D. R., Zeldin, D. C., Hoffman, S. M., Maltais, L. J., Wain, H. M., et al. (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14, 1-18.
17. Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6, 1-42.
18. Amacher, D. E. (2010) The effects of cytochrome P450 induction by xenobiotics on endobiotic metabolism in pre-clinical safety studies. Toxicol. Mech. Methods 20, 159-166.
19. Gachon, F., Olela, F. F., Schaad, O., Descombes, P., and Schibler, U. (2006) The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab. 4, 25-36.
20. Brownie, A. C., Kramer, R. E., and Gallant, S. (1979) The cholesterol side chain cleavage system of the rat adrenal cortex and its relationship to the circadian rhythm. Endocrinology 104, 1266-1269.
21. Lavery, D. J., Lopez-Molina, L., Margueron, R., Fleury-Olela, F., Conquet, F., et al. (1999) Circadian expression of the steroid 15 alpha-hydroxylase (Cyp2a4) and coumarin 7-hydroxylase (Cyp2a5) genes in mouse liver is regulated by the PAR leucine zipper transcription factor DBP. Mol. Cell. Biol. 19, 6488-6499.
22. Lee, Y. H., Alberta, J. A., Gonzalez, F. J., and Waxman, D. J. (1994) Multiple, functional DBP sites on the promoter of the cholesterol 7 alpha-hydroxylase P450 gene, CYP7. Proposed role in diurnal regulation of liver gene expression. J. Biol. Chem. 269, 14681-14689.
23. Handschin, C. and Meyer, U. A. (2003) Induction of drug metabolism: the role of nuclear receptors. Pharmacol. Rev. 55, 649-673.
24. Yang, X., Downes, M., Yu, R. T., Bookout, A. L., He, W., et al. (2006) Nuclear receptor expression links the circadian clock to metabolism. Cell 126, 801-810.
25. Kang, H. S., Angers, M., Beak, J. Y., Wu, X., Gimble, J. M., et al. (2007) Gene expression profiling reveals a regulatory role for ROR alpha and ROR gamma in phase I and phase II metabolism. Physiol. Genomics 31, 281-294.
26. Claudel, T., Cretenet, G., Saumet, A., and Gachon, F. (2007) Crosstalk between xenobiotics metabolism and circadian clock. FEBS Lett. 581, 3626-3633.
27. Froy, O. (2009) Cytochrome P450 and the biological clock in mammals. Curr. Drug Metab. 10, 104-115.
28. Koike, N., Yoo, S. H., Huang, H. C., Kumar, V., Lee, C., et al.Transcriptional architecture and chromatin landscape of the core circadian clock in mammals. Science 338, 349-354.
29. Hatanaka, F., Matsubara, C., Myung, J., Yoritaka, T., Kamimura, N., et al. (2010) Genome-wide profiling of the core clock protein BMAL1 targets reveals a strict relationship with metabolism. Mol. Cell. Biol. 30, 13.
30. Kaasik, K. and Lee, C. C. (2004) Reciprocal regulation of haem biosynthesis and the circadian clock in mammals. Nature 430, 467-471.
31. Gao, J. and Xie, W. (2010) Pregnane X receptor and constitutive androstane receptor at the crossroads of drug metabolism and energy metabolism. Drug Metab. Dispos. 38, 2091-2095.
32. Hafner, M., Juvan, P., Rezen, T., Monostory, K., Pascussi, J. M., et al. (2011) The human primary hepatocyte transcriptome reveals novel insights into atorvastatin and rosuvastatin action. Pharmacogenet. Genomics 21, 741-750.
33. Takeda, N. and Maemura, K.Circadian clock and cardiovascular disease. J. Cardiol. 57, 249-256.
34. Takeda, N. and Maemura, K.Cardiovascular disease, chronopharmacotherapy, and the molecular clock. Adv. Drug Deliv. Rev. 62, 956-966.
35. Levi, F. and Schibler, U. (2007) Circadian rhythms: mechanisms and therapeutic implications. Ann. Rev. Pharmacol. Toxicol. 47, 593-628.
36. Arendt, J. (2010) Shift work: coping with the biological clock. Occup Med 60, 10-20.
37. Levi, F., Okyar, A., Dulong, S., Innominato, P. F., and Clairambault, J. (2010) Circadian timing in cancer treatments. Annu. Rev. Pharmacol. Toxicol. 50, 377-421.
38. Ohdo, S. (2010) Chronopharmaceutics: pharmaceutics focused on biological rhythm. Biol. Pharm. Bull. 33, 159-167.
39. Levi, F., Focan, C., Karaboue, A., de la Valette, V., Focan-Henrard, D., et al. (2007) Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev 59, 1015-1035.
40. Barnes, P., FitzGerald, G., Brown, M., and Dollery, C. (1980) Nocturnal asthma and changes in circulating epinephrine, histamine, and cortisol. N. Engl. J. Med. 303, 263-267.
41. Sutherland, E. R. (2005) Nocturnal asthma: underlying mechanisms and treatment. Curr. Allergy Asthma Rep 5, 161-167.
42. Smolensky, M. H. and Peppas, N. A. (2007) Chronobiology, drug delivery, and chronotherapeutics. Adv. Drug Deliv. Rev. 59, 828-851.
43. Pincus, D. J., Beam, W. R., and Martin, R. J. (1995) Chronobiology and chronotherapy of asthma. Clin. Chest Med. 16, 699-713.
44. Taburet, A. M. and Schmit, B. (1994) Pharmacokinetic optimisation of asthma treatment. Clin. Pharmacokinet. 26, 396-418.
45. Turkoski, B. B. (1998) Medication timing for the elderly: the impact of biorhythms on effectiveness. Geriatr. Nurs. 19, 146-151.
46. Konturek, P. C., Brzozowski, T., and Konturek, S. J. (2011) Gut clock: implication of circadian rhythms in the gastrointestinal tract. J. Physiol. Pharmacol. 62, 139-150.
47. Singh, R., Sharma, P. K., and Malviya, R. (2010) Review on chronotherapeutics-A new remedy in the treatment of various diseases. Eur. J. Biol. Sci. 2, 10.
48. Schernhammer, E. S., Laden, F., Speizer, F. E., Willett, W. C., Hunter, D. J., et al. (2001) Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J. Natl. Cancer Inst. 93, 1563-1568.
49. Conlon, M., Lightfoot, N., and Kreiger, N. (2007) Rotating shift work and risk of prostate cancer. Epidemiology 18, 182-183.
50. Granda, T. G. and Levi, F. (2002) Tumor-based rhythms of anticancer efficacy in experimental models. Chronobiol. Int. 19, 21-41.
51. Levi, F., Misset, J. L., Brienza, S., Adam, R., Metzger, G., et al. (1992) A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 69, 893-900.
52. Buttgereit, F., Burmester, G. R., Straub, R. H., Seibel, M. J., and Zhou, H.Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum. 63, 1-9.
53. Buttgereit, F., Mehta, D., Kirwan, J., Szechinski, J., Boers, M., et al. (2012) Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann. Rheum. Dis 72, 204-210.
54. Dickmeis, T. (2009) Glucocorticoids and the circadian clock. J. Endocrinol. 200, 3-22.